Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented recurrent endometrial adenocarcinoma, papillary serous (UPSC), or mixed mullerian tumor (MMT) for which a cure or substantial palliation is unlikely using surgery and/or radiotherapy. Patients must have measurable disease or disease felt to be reproducibly measurable on CT scan, chest x-ray and/or tumor marker elevations .~* Recurrent ovarian or primary peritoneal cancers as defined as either:~  1. Measurable disease either by physical examination or by imaging or~ 2. Non-measurable evidence of disease such as any or all of the following standard Rustin criteria:~     1. Peritoneal implants \<2 cm~    2. Abnormal densities on computerized tomography (CT) scan and/or loculated fluid collections~    3. Elevated CA-125 (\>100 U/mL on 2 measurements at least 1 week apart) and disease- related symptoms.~* Patients with the following histologic ovarian or uterine epithelial cell types are eligible:~  * Serous adenocarcinoma~ * Endometrioid adenocarcinoma~ * Mucinous adenocarcinoma~ * Undifferentiated carcinoma~ * Clear cell adenocarcinoma~ * Mixed epithelial carcinoma~ * Transitional cell~ * Malignant Brenner's tumor~ * Adenocarcinoma NOS~* Age ≥ 18 years.~* ECOG performance status of ≤ 2.~* Peripheral neuropathy must be ≤ grade 1~* Previously treated patients must have received no antineoplastic treatment for at least 4 weeks. Patients will not have received more than two previous chemotherapy regimens.~* In patients previously irradiated, the recurrent disease should be outside of the radiotherapy portal or have developed disease progression within the radiated field.~* No concurrent chemotherapy, radiotherapy, immunotherapy, or hormone therapy.~* Hepatic:~  * Total bilirubin ≤ ULN~ * AST and ALT and alkaline phosphatase must be within the range allowing for eligibility.~* Patients must be alert, oriented, and have signed an informed consent in accordance with institutional policies and be aware of the investigational nature of the study.~* Women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter~Exclusion Criteria:~* Patient has impairment of hepatic, renal or hematologic function as defined by the following baseline laboratory values:~  1. Serum creatinine clearance ≤ 50 ml/min~ 2. Platelets \<100,000/mm3~ 3. Absolute neutrophil count (ANC) \<1500/mm3~ 4. Hemoglobin \<8.0 g/dl (the patient may be transfused prior to study entry)~* History of chronic or active hepatitis~* Patient has severe or uncontrolled medical disease (eg. uncontrolled diabetes, unstable angina, myocardial infarction within 6 months, congestive heart failure, etc.)~* Patients with dementia or altered mental status that would prohibit the giving and understanding of informed consent at time of study entry.~* Patients with a history of severe hypersensitivity to Taxotere®, Topotecan®, or other drugs formulated with polysorbate 80.~* Women who are pregnant or breast-feeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete